The Meeting

7GC & Co. Holdings Inc. Announces Postponement of its Special Meeting of Stockholders to December 21, 2022 and That Trust Account Will Bear Interest and Will Not Be Decreased Due to Excise Tax

Retrieved on: 
Monday, December 19, 2022
Interest on Lawyer Trust Accounts, Calendar, Date, Proxy statement, Meeting, Proxy, Bank account, Inflation, SAN, Extension, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., The Meeting, Sponsor, VII, Business architecture, Holding company

The record date for determining the Company stockholders entitled to receive notice of and to vote at the Meeting remains the close of business on November 21, 2022 (the “Record Date”).

Key Points: 
  • The record date for determining the Company stockholders entitled to receive notice of and to vote at the Meeting remains the close of business on November 21, 2022 (the “Record Date”).
  • Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action.
  • Stockholders as of the Record Date can vote, even if they have subsequently sold their shares.
  • Additionally, if the Extension is implemented, the Company plans to maintain the remaining amount in its trust account (the “Trust Account”) in an interest-bearing demand deposit account at a bank.

HCM Acquisition Corp Requests that Public Shareholders Indicate their Intention as to Election Reversals

Retrieved on: 
Monday, December 19, 2022
Transfer, Roman Catholic Diocese of La Crosse, Trust, Privacy Office of the U.S. Department of Homeland Security, Commitment, HCM, Meeting, Treasury, Maxima and minima, Inflation, Security (finance), The Meeting, Nature, Proposal, Extraordinary general meeting, U.S. Department of the Treasury, Office of Inspector General, Our Boarding House, Continental, Mechanics

If the Board of Directors abandons the Proposals, no redemptions will be honored prior to the Original Termination Date, or April 25, 2023.

Key Points: 
  • If the Board of Directors abandons the Proposals, no redemptions will be honored prior to the Original Termination Date, or April 25, 2023.
  • A public shareholder that has made a Redemption Election may withdraw its Redemption Election with respect to all or a portion of their public shares for which it previously submitted a Redemption Election (an “Election Reversal”).
  • See the portion of our proxy entitles “The Proposals — Redemption Withdrawal Procedures.”
    The Company requests that public shareholders (i) indicate their intention to make an Election Reversal on their Reversal Commitment Form and (ii) make Election Reversals, in each case, for no less than twenty-five percent (25%) of such shareholder’s public shares (the “Minimum Non-Redemption Percentage”).
  • The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased.

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

Retrieved on: 
Friday, January 6, 2023
Linda, Trial master file, OTCQB, Biotechnology, Annual general meeting, PIP, Northwest Biotherapeutics, Certificate, R, The Meeting, Annual Meetings of the International Monetary Fund and the World Bank Group, Patient, Q & A, Consultant, JAMA Oncology, The, New Year, Documentation, Q&A, Holding company, Pharmaceutical industry, Financial adviser, Video game console, Sawston

BETHESDA, Md., Jan. 6, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on December 30, 2022, and discussion at the Meeting (which was publicly available) about achievements in 2022 and anticipated activities in 2023.

Key Points: 
  • There was a strong vote turnout at the Annual Meeting, with votes cast for 78% of all common and preferred shares that were outstanding as of the record date (841,223,911 votes cast).
  • Building upon the achievements and progress in 2022, the Company believes that 2023 can be another very strong year.
  • Linda Powers, the Company's CEO, commented:  "2022 has been a year of major accomplishments, and we look forward to an even stronger 2023.
  • We are very grateful for the ongoing strong support from our shareholders, as reflected in the exceptional voting results of the Annual Meeting."

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

Retrieved on: 
Friday, January 6, 2023
Linda, Trial master file, OTCQB, Biotechnology, Annual general meeting, PIP, Northwest Biotherapeutics, Certificate, R, The Meeting, Annual Meetings of the International Monetary Fund and the World Bank Group, Patient, Q & A, Consultant, JAMA Oncology, The, New Year, Documentation, Q&A, Holding company, Pharmaceutical industry, Financial adviser, Video game console, Sawston

BETHESDA, Md., Jan. 6, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on December 30, 2022, and discussion at the Meeting (which was publicly available) about achievements in 2022 and anticipated activities in 2023.

Key Points: 
  • There was a strong vote turnout at the Annual Meeting, with votes cast for 78% of all common and preferred shares that were outstanding as of the record date (841,223,911 votes cast).
  • Building upon the achievements and progress in 2022, the Company believes that 2023 can be another very strong year.
  • Linda Powers, the Company's CEO, commented:  "2022 has been a year of major accomplishments, and we look forward to an even stronger 2023.
  • We are very grateful for the ongoing strong support from our shareholders, as reflected in the exceptional voting results of the Annual Meeting."

SNDL and Nova Cannabis Announce Transformational Strategic Partnership Creating a Sustainable Canadian Cannabis Retail Platform

Retrieved on: 
Wednesday, December 21, 2022
COVID-19, News, Proxy, Cannabis, Risk, MI, LLP, Annual report, Toronto Stock Exchange, Partnership, TSX, Stikeman Elliott, Net interest margin, Accretion/dilution analysis, Private sector, Capital, Corporation, The Company, Canadian House of Commons Special Committee on Electoral Reform, Multilateral, Growth, Committee, License, The Meeting, AB, Multimedia, Security (finance), Cyprus Securities and Exchange Commission, SEDAR, Wine, System, SG, Intellectual property, Transaction, Agreement, Legislation, Investment, Drug, Animal, Bank, Audit, Superette

Nova will also have a right of first refusal on SNDL's Canadian cannabis retail pipeline.

Key Points: 
  • Nova will also have a right of first refusal on SNDL's Canadian cannabis retail pipeline.
  • Increased Liquidity: SNDL plans to reduce its equity ownership in Nova to below 20% through a capital distribution of Nova Shares owned by SNDL to SNDL shareholders.
  • Creates sustainable regulated retail network in Canada: The Agreement provides a low-cost operating platform for Nova, driven by SNDL's scale across cannabis and alcohol.
  • Pure-play retail exposure for SNDL shareholders: A share capital distribution of Nova Shares provides SNDL shareholders the optionality of equity exposure to a well-capitalized Canadian retail platform.

GlobalBlock Reports AGM Voting Results and Grant of Stock Options

Retrieved on: 
Wednesday, December 7, 2022
Blockchain.com, UAB, OTC Markets Group, FSE, Remuneration, TSX, The Meeting, Meeting, Security (finance)

A total of 53,154,500 common shares, or 50.65% of the issued and outstanding common shares of the Company were represented at the Meeting.

Key Points: 
  • A total of 53,154,500 common shares, or 50.65% of the issued and outstanding common shares of the Company were represented at the Meeting.
  • The Company also announces the grant of incentive stock options to acquire a total of 100,000 common shares of the Company at an exercise price of $0.25 per share, with such options to vest one-half on the first anniversary of the date of grant and the remaining one-half on the second anniversary of the date of grant.
  • The options expire five (5) years from the date of grant.
  • Currently, GlobalBlock Europe only accepts United Kingdom and Lithuania resident clients or customers, and certain clients or customers that initiate contact with GlobalBlock Europe, for its digital asset broker or trading services.

AF ACQUISITION CORP. ANNOUNCES CHANGE OF SPECIAL MEETING OF STOCKHOLDERS DATE TO DECEMBER 19, 2022

Retrieved on: 
Friday, December 16, 2022
Acquisition, Trust, Charter, Communication, Person, Sale, Proxy statement, Prospectus, Name, Proxy, The Meeting, Meeting, Wind, Security (finance)

Palm Beach, FL, Dec. 16, 2022 (GLOBE NEWSWIRE) -- AF Acquisition Corp. (“AF” or the “Company”) (Nasdaq: “AFAQU”, “AFAQ”, “AFAQW”) announced today that the special meeting in lieu of annual meeting of stockholders (the “Meeting”) originally scheduled for Thursday, December 15, 2022, has been adjourned to Monday, December 19, 2022.

Key Points: 
  • Palm Beach, FL, Dec. 16, 2022 (GLOBE NEWSWIRE) -- AF Acquisition Corp. (“AF” or the “Company”) (Nasdaq: “AFAQU”, “AFAQ”, “AFAQW”) announced today that the special meeting in lieu of annual meeting of stockholders (the “Meeting”) originally scheduled for Thursday, December 15, 2022, has been adjourned to Monday, December 19, 2022.
  • As a result of this change, the Meeting will now be held at 9:00 a.m. Eastern Time, on December 19, 2022, via a live webcast at https://www.cstproxy.com/afacq.com .
  • The Company plans to solicit proxies from stockholders during the period prior to the Meeting.
  • Only the holders of the Company’s common stock as of the close of business on November 18, 2022, the record date for the Meeting, are entitled to vote at the Meeting.

InterPrivate III Financial Partners Inc. Announces Amendment and Supplements to it Definitive Proxy Statement

Retrieved on: 
Thursday, December 15, 2022
Acquisition, Inflation, Annual report, Charter, DGCL, NYSE, Person, Communication, Security (finance), Sale, Proxy statement, Prospectus, Trust, IPO, Form 10-K, Special, Extension, Tax, Risk, Business architecture, Liquidation, The Meeting, Proxy, Uncertainty, Meeting, Life Partners, Inc.

Pursuant to the Charter, the Company has until March 9, 2023 to consummate an initial business combination.

Key Points: 
  • Pursuant to the Charter, the Company has until March 9, 2023 to consummate an initial business combination.
  • About InterPrivate III Financial Partners Inc.
    InterPrivate III Financial Partners Inc. (the “Company”) is a blank check company incorporated in Delaware on September 10, 2020.
  • It was originally incorporated under the name “InterPrivate II Financial Holdings Corp.”, but the Company changed its name to “InterPrivate III Financial Partners Inc.” on January 6, 2021.
  • Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests are contained in the Proxy Statement (defined below).

Interprivate IV Infratech Partners Inc. Announces Amendment and Supplements to its Definitive Proxy Statement

Retrieved on: 
Thursday, December 15, 2022
Acquisition, Inflation, Annual report, Charter, DGCL, Person, Communication, Security (finance), Sale, Proxy statement, Prospectus, Trust, IPO, Form 10-K, Special, Extension, Tax, Risk, Business architecture, Liquidation, The Meeting, Proxy, Uncertainty, Meeting, Life Partners, Inc.

Pursuant to the Charter, the Company has until March 9, 2023 to consummate an initial business combination.

Key Points: 
  • Pursuant to the Charter, the Company has until March 9, 2023 to consummate an initial business combination.
  • About InterPrivate IV InfraTech Partners Inc.
    InterPrivate IV InfraTech Partners Inc. is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
  • The Company intends to focus on a target business in the technology, media and telecom infrastructure space.
  • Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests are contained in the Proxy Statement (defined below).